Zimbabwe has turned down a substantial US healthcare agreement worth 367 million US dollars (£272m) spanning five years because of the United States' insistence on sensitive biological samples.
This move came to light after a government memo dated December was leaked, indicating that President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesperson has since explained that the United States was seeking biological samples for research and commercial gain while refused to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for more talks to find a deal suitable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Implications
This development follows a comparable situation in Kenya, where a court blocked a related health funding agreement following concerns were raised about the security of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and accountability.
Based on reports, Sixteen African countries have so far agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery with no certainty that the end products would be available to our citizens if a future pandemic arise."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending structures already set up via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This framework is intended to guarantee that when a nation provides its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how future collaboration might be designed in a way that respects the independence and dignity of both nations."
Health Experts Reaction
A leading public health body stated it understood the official position, but urged that talks need to persist since much of the country's Aids initiatives depended on external financing.
"If specific concerns arise, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
This impasse emphasises the continuing tensions between receiving vital international aid and safeguarding a country's data in an increasingly data-driven world.